- Open Access
Correction to: Novel and emerging therapies for B cell lymphoma
Journal of Hematology & Oncology volume 14, Article number: 28 (2021)
Correction to: Journal of Hematology & Oncology (2019) 12:82 https://doi.org/10.1186/s13045-019-0752-3
There is an error in Table 1 of the original article. Lisocabtagene maraleucel (liso-cel) is administered as a flat dose of 1 × 108 CAR T cells, regardless of a patient’s weight. The table incorrectly lists the dose as 1 × 108 cells/kg.
Ayyappan S, Maddocks K. Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2019;12(1):82. https://doi.org/10.1186/s13045-019-0752-3.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ayyappan, S., Maddocks, K. Correction to: Novel and emerging therapies for B cell lymphoma. J Hematol Oncol 14, 28 (2021). https://doi.org/10.1186/s13045-020-01022-w